Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS") and multiple sclerosis ("MS"). The company recently secured a new $10 million debt facility, which enables the payoff of another higher interest rate loan and the finance of operations to generate additional data to support the new drug application of lead drug candidate CNM-Au8 for ALS.

"We believe that the proceeds from this new debt facility, including an extended interest-only period, will allow Clene the cash runway to generate the additional data the U.S. Food and Drug Administration has requested from our expanded access programs," said Clene CEO and President Rob Etherington. "The data are being gathered to support the existing clinical study data for inclusion in an application seeking approval of CNM-Au8 for ALS through the accelerated regulatory pathway."

To view the full article, visit https://ibn.fm/0eqoN

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Wednesday's trading session at $5.28, off by 10.3565%, on 125,714 volume. The average volume for the last 3 months is 97,987 and the stock's 52-week low/high is $3.8181/$11.00.

Recent News

• Clene Inc. (NASDAQ: CLNN) - BioMedNewsBreaks - Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS
• Study Sheds Light on How Mitochondrial Changes Contribute to Muscle Aging
• Clene Inc. (NASDAQ: CLNN) Improves Cash Position and Runway with New Debt Facility for CNM-Au8(R) Data Collection to Support Accelerated Approval Application

Thumzup Media Corp. (NASDAQ: TZUP)

The QualityStocks Daily Newsletter would like to spotlight Thumzup Media Corp.(NASDAQ: TZUP).

Thumzup (NASDAQ: TZUP) announced the purchase of 9.783 Bitcoin for approximately $1 million at an average price of $102,220 per BTC, as part of its Treasury Asset Strategy. The company has requested Board approval to allocate up to 90% of its liquid assets for ongoing Bitcoin purchases. Coinbase (Nasdaq: COIN) provides custodial and self-custodial wallet services for Thumzup's Bitcoin holdings. The company also plans to begin paying gig-economy workers in Bitcoin in the coming weeks, adhering to all relevant laws and regulations.

To view the full press release, visit https://ibn.fm/idumo

Thumzup Media Corp. (NASDAQ: TZUP) is at the forefront of modernizing the social media branding and marketing industry with its unique platform designed to connect advertisers directly with everyday social media users. The company’s mission is to empower individuals by turning their authentic social media activity into a monetizable asset while providing brands with cost-effective and impactful advertising solutions.

Through its flagship Thumzup platform, the company offers a seamless system where users post about participating advertisers and receive cash payments via Venmo or PayPal. Thumzup recently announced plans to integrate bitcoin as an additional payment option, expanding accessibility for gig economy workers.

By prioritizing accessibility and transparency, Thumzup is redefining traditional marketing strategies with an inclusive, user-driven approach. It is leveraging its scalable technology to disrupt the status quo, offering a win-win ecosystem for advertisers and users alike.

The company is headquartered in Los Angeles, California.

Products

Thumzup’s key offering, the Thumzup platform, features two integrated components: a sophisticated advertiser dashboard and an intuitive consumer-facing app. The advertiser dashboard provides companies with tools to design, manage, and analyze campaigns.

On the consumer side, the Thumzup app allows users to participate in campaigns by posting approved content to their social media accounts. In exchange, users receive direct cash rewards.

Recent enhancements to the platform include the launch of video capabilities, enabling integration with Instagram Reels. This update allows advertisers to tap into the growing popularity of short-form video content, broadening campaign possibilities.

The platform not only incentivizes users but also delivers authentic, relatable content for advertisers, bridging the gap between grassroots engagement and effective campaign management.

Market Opportunity

The global social media advertising market is projected to reach $219.8 billion in 2024, with an expected annual growth rate of 3.86%, resulting in a market volume of $255.8 billion by 2028, according to Statista. Thumzup targets the intersection of this growth with the rise of micro-influencers and everyday social media users, a segment that remains largely untapped in the advertising ecosystem.

In October 2024, Thumzup achieved 202% year-over-year growth in advertisers on its proprietary platform, demonstrating significant traction and scalability. With plans for further expansion in both advertiser partnerships and user engagement, the company is well-positioned to capitalize on the growing demand for authentic and trust-building marketing strategies. As Thumzup integrates innovative features like video support and continues its geographic expansion, it is poised to capture a larger share of the rapidly growing social media advertising market.

Leadership Team

Robert Steele, Founder and Chief Executive Officer of Thumzup, has over 25 years of experience as a technologist and entrepreneur. He has successfully launched multiple companies, including iBrite, a pioneer in mobile software development. Mr. Steele’s leadership and innovative vision drive Thumzup’s mission to democratize the social media marketing industry.

Robert Haag, Director of Thumzup, is the Managing Member of Westside Strategic Partners LLC and a Managing Director at IRTH Communications. With decades of experience in financial communications, investment, and corporate strategy, Mr. Haag provides critical guidance on strategic initiatives and business growth.

Dr. Joanna Massey, member of the company’s Board of Advisors, brings over 25 years of executive experience with Fortune 500 companies and startups to Thumzup. She has held senior roles in communications at Lions Gate Entertainment and CBS Corporation. Dr. Massey leverages her expertise to support Thumzup’s growth strategy.

Thumzup Media Corp. (NASDAQ: TZUP), closed Wednesday's trading session at $3.63, off by 6.9231%, on 76,144 volume. The average volume for the last 3 months is 302,854 and the stock's 52-week low/high is $2.76/$7.89.

Recent News

• Thumzup Media Corp. (NASDAQ: TZUP) - InvestorNewsBreaks - Thumzup Media Corp. (NASDAQ: TZUP) Invests $1 Million in Bitcoin as Part of Treasury Asset Strategy
• TechMediaBreaks - Thumzup Media Corp. (NASDAQ: TZUP) Eyes Continued Adoption of Flagship Platform
• Thumzup Media Corp. (NASDAQ: TZUP) Expands into Vibrant South Florida Market as Part of Broader Growth Strategy

SolarBank Corp. (CSE: SUNN) (NASDAQ: SUUN)

The QualityStocks Daily Newsletter would like to spotlight The Coretec Group Inc.

The QualityStocks Daily Newsletter would like to spotlight SolarBank Corp. (CSE: SUNN) (NASDAQ: DGDCF).

SolarBank has a development pipeline exceeding 1 GW, with over 100 MW of renewable energy projects completed.

The company operates a vertically integrated business model, ensuring cost efficiency and maximizing profitability across the project lifecycle.

SolarBank recently secured a $25.8 million project finance facility for two BESS projects, demonstrating robust financial backing.

Announced expansion into the rapidly growing data center market positions the company to tap into an industry that's forecast to reach a value of $395 billion by 2030.

Leadership with over 100 years of combined experience ensures strong operational expertise and strategic vision.

SolarBank's diverse portfolio spans solar PV, BESS and EV charging projects, reducing exposure to market volatility.

Strong partnerships with corporate clients and municipalities support long-term revenue generation and scalability.

SolarBank is covered by H.C. Wainwright & Co. and Research Capital Corporation.

SolarBank (NASDAQ: SUUN) (CSE: SUNN) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the United States. The company is committed to advancing the transition to sustainable energy by offering end-to-end services that include project origination, financing structuring, engineering, procurement, construction, and long-term operations and maintenance. SolarBank focuses on delivering innovative energy solutions through solar photovoltaic systems, battery energy storage systems ("BESS"), and electric vehicle ("EV") charging infrastructure.

SolarBank Corporation (NASDAQ: SUUN) (CSE: SUNN) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the United States. The company is committed to advancing the transition to sustainable energy by offering end-to-end services that include project origination, financing structuring, engineering, procurement, construction, and long-term operations and maintenance. SolarBank focuses on delivering innovative energy solutions through solar photovoltaic systems, battery energy storage systems (BESS), and electric vehicle (EV) charging infrastructure.

With a vision to provide scalable and reliable clean energy solutions, SolarBank has established itself as a leader in the renewable energy market by cultivating partnerships with utilities, commercial and industrial entities, municipalities, and residential customers. Its vertically integrated business model allows for optimized efficiency, cost management, and returns across diverse markets in North America. This end-to-end approach ensures greater control over project quality, costs, and operational outcomes, strengthening its competitive position.

Driven by a mission to create a greener future, SolarBank manages a robust portfolio of projects, including more than 100 megawatts (MW) of developed capacity and a pipeline exceeding one gigawatt (GW). The company’s commitment to sustainability and innovation makes it a recognized player in the renewable energy sector.

SolarBank has offices in Toronto, Ontario and New York.

Projects

SolarBank boasts an impressive and diverse portfolio of renewable energy initiatives that underline its leadership in the clean energy space. In the U.S., the company has over 250 MW of solar projects under development, principally in New York, focusing on community solar farms and commercial and industrial installations. Notably, SolarBank is developing several community solar projects in upstate New York, which will deliver clean energy to local residents and small businesses. Community solar projects, which are a cornerstone of SolarBank’s portfolio, provide scalable solutions for renters, homeowners, and small businesses to access affordable renewable energy, driving localized energy independence and economic savings.

In Canada, SolarBank has been a significant participant in Ontario’s Feed-in-Tariff program, where it has secured contracts for close to 200 MW of capacity. Its current management includes 70 solar power projects, totaling 28.8 MW of operational solar assets. The company’s expertise extends to the development and ownership of battery energy storage systems and EV charging stations, further diversifying its portfolio.

The company’s vertically integrated approach spans the entire project lifecycle, from initial site acquisition and grid interconnection to long-term operation and maintenance services. This ensures seamless execution and high-quality outcomes, providing value to stakeholders and supporting the transition to a clean energy future.

Market Opportunity

SolarBank operates within a growing renewable energy market driven by global demand for sustainable power solutions. In North America, favorable policies such as the Inflation Reduction Act in the United States and Canada’s investments in green technologies provide a robust foundation for renewable energy adoption. Solar PV installations and battery energy storage systems are at the forefront of this expansion, addressing energy reliability and grid stability while reducing carbon emissions.

The North American solar PV market was valued at $25.02 billion in 2019 and is projected to reach $120.74 billion by 2027, growing at a compound annual growth rate (CAGR) of 21.7% from 2020 to 2027. Likewise, the global BESS market is expected to expand from $7.8 billion in 2024 to $25.6 billion by 2029, at a CAGR of 26.9%, as reported by MarketsandMarkets. These trends are driven by the increasing integration of renewable energy sources, the need for grid resilience, and declining technology costs.

SolarBank’s operations have it well-positioned to capitalize on these opportunities. With a development pipeline exceeding one gigawatt (GW), the company is focused on meeting growing demand in community and commercial solar sectors. Decentralized energy solutions, such as virtual net metering and behind-the-meter systems, further enhance SolarBank’s market potential by addressing the critical need for flexible, cost-effective, and sustainable energy infrastructure. By leveraging its vertically integrated model and diversified portfolio, SolarBank stands as a key player in driving the renewable energy transition.

Leadership Team

Dr. Richard Lu, MD, MSc., MHSc., MBA, serves as President and CEO of SolarBank, bringing over 25 years of global energy experience. His leadership has been instrumental in advancing the company’s strategic initiatives across North America, Europe, and Asia, with a focus on renewable energy development and operational excellence.

Sam Sun, MBA, is the Chief Financial Officer of SolarBank. A Chartered Professional Accountant with more than 15 years of expertise in corporate finance, Mr. Sun has overseen financial strategies and internal controls across the cleantech, manufacturing, and mining sectors in Canada, the U.S., and China.

Andrew van Doorn, PE, serves as Chief Operating Officer, with nearly three decades of experience in engineering and construction. Mr. van Doorn has successfully led projects totaling over 200 MW of solar capacity and is a former Chairman of the Canadian Solar Industries Association.

Tracy Zheng, MBA, Chief Development Officer, has over 25 years of experience in brand marketing, business development, and solar project operations. She has spearheaded sales initiatives, conducted feasibility studies, and negotiated key partnerships that drive SolarBank’s growth.

Matt Wayrynen, Executive Chairman and Director, has a background in resource company management, venture capital, and mergers and acquisitions. Under his leadership, Solar Flow-Through Funds, where Mr. Wayrynen acted as CEO, was acquired by SolarBank, enhancing its asset portfolio and growth prospects.

---

Forward Looking Statements

This report contains forward-looking statements and forward-looking information ‎within the meaning of Canadian securities legislation (collectively, “forward-looking ‎statements”) that relate to the Company’s current expectations and views of future events. ‎Any statements that express, or involve discussions as to, expectations, beliefs, plans, ‎objectives, assumptions or future events or performance (often, but not always, through the ‎use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will ‎continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, ‎‎”projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be ‎forward-looking statements and may involve estimates, assumptions and uncertainties ‎which could cause actual results or outcomes to differ materially from those expressed in ‎such forward-looking statements. In particular and without limitation, this report ‎contains forward-looking statements pertaining to the Company’s expectations regarding its industry trends and overall market growth of the data center market; the Company’s expansion into the data center market, including its pursuit of opportunities as a developer, owner, and strategic partner in data center infrastructure; supporting the demand for high-performance, sustainable energy solutions within the sector; details of the company’s business plan including development of solar power projects, battery storage projects and EV charging projects; the completion of any contracts for, or construction of, any data center, solar power, battery storage or EV projects; the receipt of interconnection approval, permits and financing to be able to construct projects; the receipt of incentives for projects; and the size of the Company’s development pipeline. No assurance ‎can be given that these expectations will prove to be correct and such forward-looking ‎statements included in this report should not be unduly relied upon. These ‎statements speak only as of the date of this report.‎

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. In making the forward looking statements included in this report, the Company has made various material assumptions, including but not limited to: obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and services offered by the Company’s competitors; that the Company’s current good relationships with its service providers and other third parties will be maintained; and government subsidies and funding for renewable energy will continue as currently contemplated. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements.

Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Forward-‎Looking Statements” and “Risk ‎Factors” in the Company’s most recently completed Annual Information Form, and other public filings of the Company, which include: the Company may be adversely affected by volatile solar power market and industry conditions; the execution of the Company’s growth strategy depends upon the continued availability of third-party financing arrangements; the Company’s future success depends partly on its ability to expand the pipeline of its energy business in several key markets; governments may revise, reduce or eliminate incentives and policy support schemes for solar and battery storage power; general global economic conditions may have an adverse impact on our operating performance and results of operations; the Company’s project development and construction activities may not be successful; developing and operating solar projects exposes the Company to various risks; the Company faces a number of risks involving Power Purchase Agreements (“PPAs”) and project-level financing arrangements; any changes to the laws, regulations and policies that the Company is subject to may present technical, regulatory and economic barriers to the purchase and use of solar power; the markets in which the Company competes are highly competitive and evolving quickly; an anti-circumvention investigation could adversely affect the Company by potentially raising the prices of key supplies for the construction of solar power projects; foreign exchange rate fluctuations; a change in the Company’s effective tax rate can have a significant adverse impact on its business; seasonal variations in demand linked to construction cycles and weather conditions may influence the Company’s results of operations; the Company may be unable to generate sufficient cash flows or have access to external financing; the Company may incur substantial additional indebtedness in the future; the Company is subject to risks from supply chain issues; risks related to inflation; unexpected warranty expenses that may not be adequately covered by the Company’s insurance policies; if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the renewable energy market; there are a limited number of purchasers of utility-scale quantities of electricity; compliance with environmental laws and regulations can be expensive; corporate responsibility may adversely impose additional costs; the future impact of any resurgence of COVID-19 on the Company is unknown at this time; the Company has limited insurance coverage; the Company will be reliant on information technology systems and may be subject to damaging cyberattacks; the Company may become subject to litigation; there is no guarantee on how the Company will use its available funds; the Company will continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders; and future dilution as a result of financings.

The Company undertakes no obligation to update or revise any ‎forward-looking statements, whether as a result of new information, future events or ‎otherwise, except as may be required by law. New factors emerge from time to time, and it ‎is not possible for the Company to predict all of them, or assess the impact of each such ‎factor or the extent to which any factor, or combination of factors, may cause results to ‎differ materially from those contained in any forward-looking statement. Any forward-‎looking statements contained in this report are expressly qualified in their entirety by ‎this cautionary statement.‎

SolarBank Corp. (NASDAQ: SUUN), closed Wednesday's trading session at $2.18, off by 5.2174%, on 12,846 volume. The average volume for the last 3 months is 32,249 and the stock's 52-week low/high is $1.95/$7.50.

Recent News

• SolarBank Corp. (CSE: SUNN) (NASDAQ: SUUN) - SolarBank Corp. (NASDAQ: SUUN) (CSE: SUNN) Is 'One to Watch'
• InvestorNewsBreaks - SolarBank Corp. (NASDAQ: SUUN) (CSE: SUNN) (NEO: SUNN) (FSE: GY2) Secures $25.8M Finance Facility
• InvestorNewsBreaks - SolarBank Corp. (NASDAQ: SUUN) (CSE: SUNN) Sells New York Solar Projects to Qcells in $49.5 Million Deal

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF)

The QualityStocks Daily Newsletter would like to spotlightFathom Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF).

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF), a junior exploration company, is positioned to play a critical role amidst growth of copper and gold sectors. "The company's flagship project, the Storm Copper Project, a joint initiative by Aston Bay and American West Metals, in Nunavut, Canada, made significant advancements in 2024 and is poised for further progress in 2025," reads a recent article.

"The Storm Copper Project has gained attention for its promising assay results and high-grade copper mineralization. Spring/summer 2024 marked another successful exploration season that identified extensive copper zones, demonstrating the project's potential as a major contributor to global copper supply… Aston Bay plans to expand its exploration activities, looking to replicate the success of Storm with its Epworth Copper Project, also located in Nunavut, where surface samples have yielded up to 61% copper with 5600 g/t silver as well as cobalt, zinc and gold. The company is also exploring the high-grade (up to 62.51 g/t Au) Buckingham Gold Vein and critical-metals prospects in central Virginia."

To view the full article, visit https://ibn.fm/i4RWQ

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

The company believes in responsible exploration and carries out its work programs to the highest standards of social responsibility, environmental stewardship and health and safety. Aston Bay cares about leaving a net positive impact on the communities in which it works and engages with local representatives, Indigenous groups and government agencies to build respectful relationships through dialogue and collaborative processes. Depending on the stage of exploration, these efforts may include employment, contracting, training, community benefits and other agreements.

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet and/or exceed industry standards and government codes and regulations.

The company is headquartered in Toronto.

Projects

Storm Copper

The high-grade Storm Copper Deposit is located 112 kilometers south of the community of Resolute Bay, Nunavut, on western Somerset Island, just south of the past-producing Polaris Pb-Zn Mine. The property comprises 173 contiguous mining claims, including the Storm Copper and Seal Zinc projects, covering an area of approximately 541,795 acres.

The property has good access to established shipping lanes, and the landscape provides favorable conditions for development of roads and a protected deep-water port. Exploration is supported through excellent infrastructure in the nearby hamlet of Resolute Bay.

Aston Bay is partnered with American West Metals (ASX: AW1) at Storm. American West is responsible for all exploration expenditures, having aggressively advanced the project toward production and earned an 80% interest. This affords excellent optionality to the company’s shareholders, as Aston Bay is free carried with no required expenditures until the completion of a bankable feasibility study.

American West recently completed an Australian JORC-compliant Maiden Resource Estimate for Storm; the North American 43-101 compliant resource estimate is expected in Q1 2024. American West is cashed up and plans a multimillion-dollar resource expansion and new discovery drilling program for the summer of 2024.

The Buckingham County Gold Project

The gold-bearing system at the Buckingham County Gold Project in Virginia lies within a belt hosting past producing mines, current gold mines and advanced gold explorations, stretching through Georgia, the Carolinas, Virginia, Nova Scotia and Newfoundland.

Buckingham hosts a “Kirkland Lake-style” high grade gold vein returning values consistently over one ounce gold per ton and is underexplored both at depth and along almost one mile of strike length. These types of veins have excellent ESG qualities, as they are typically mined using a small footprint underground method, with gold extracted using simple and environmentally friendly gravity methods.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

A report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Thomas Ullrich is CEO and Director of Aston Bay. He has over 30 years of experience in mineral exploration and geoscience. Before joining Aston Bay, he was Chief Geologist North America for Antofagasta Minerals plc, investigating copper potential through extensive property evaluations and management of drill programs in the United States, Mexico and Canada. Prior to that, he was Senior Geologist for Almaden Minerals.

Sofia Harquail handles Investor Relations and Corporate Development at Aston Bay. She has over 15 years of experience in the private and public sectors of the mining industry. Before joining Aston Bay, she worked as a consultant for the Prospectors and Developers Association of Canada and for exempt market dealer Red Cloud Financial Services Inc. Ms. Harquail holds an M.A. from the University of Uppsala in Sweden and received her CPIR designation from the CIRI/Ivey Investor Relations Program. She also sits on the board of the Young Mining Professionals Toronto and is CSC Certified.

Aston Bay has a talented Board of Directors bringing broad experience from across the industry, encompassing resource expansion, mine development, mergers and acquisitions, and mining finance.

Ms. Jessie Liu-Ernsting has over 15 years of experience in the mining industry, spanning capital projects engineering, debt capital markets, private equity and corporate strategy at several firms, including Hudbay Minerals and Resource Capital Funds. She is currently VP Investor Relations and Communications at G Mining Ventures Corp.

Mr. Jeffrey R. Wilson has over 25 years’ experience in the mining industry, having served as a director, officer and advisor of multiple public and private companies in the mineral exploration and mining investment industries. Mr. Wilson is currently President & CEO of Precipitate Gold Corp.

Mr. Gary O’Connor has over 40 years of diverse experience as a mineral exploration and development professional in the management of successful resource projects as well as the evaluation, technical due diligence, and supervision of large mineral exploration and development projects through-out the world. While with Freeport, Mr. O’Connor worked on the due diligence and discovery of a major gold fraud on the Busang gold “deposit” in Kalimantan by Bre-X.

Mr. Mark J. Pryor is a geologist with a 40-year track record of successfully advancing multiple precious metal, copper, coal, REE and Li projects from discovery through to exploitation. He is currently Executive Vice President of the Exploration Division at The Electrum Group.

Aston Bay Holdings Ltd. (OTCQB: ATBHF), closed Wednesday's trading session at $0.04595, off by 6.6057%, on 1,000 volume. The average volume for the last 3 months is 317,230 and the stock's 52-week low/high is $0.031/$0.1164.

Recent News

• Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) - MiningNewsBreaks - Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Expanding Exploration, Looks to Replicate Success of Flagship Project
• The Only US Cobalt Mine Runs Out of Cash, Plans to Go Private
• RockBreaks - Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Eyes Exciting New Developments at Storm

HealthLynked Corp. (OTCQB: HLYK)

The QualityStocks Daily Newsletter would like to spotlightFathom HealthLynked Corp. (OTCQB: HLYK) .

HealthLynked Corp. (OTCQB: HLYK) is at the forefront of a transformative movement in healthcare, utilizing its extensive collection of health data to improve care for all. With a commitment to leveraging its advanced technology platforms, HealthLynked employs a sophisticated, cloud-based network that serves as a comprehensive repository for personal health data. This system not only simplifies the management and archiving of medical records but also enables the application of AI to deliver personalized healthcare insights. Through deep analysis of this data, HealthLynked’s AI capabilities help identify the root causes of diseases, tailor healthcare solutions to individual needs, and accelerate medical discoveries.

In addition to these capabilities, HealthLynked provides a user-friendly platform for booking healthcare appointments, similar to how OpenTable operates for restaurant reservations. This feature allows patients to conveniently book appointments with healthcare providers across the country, including options for telemedicine consultations, enhancing accessibility and efficiency in healthcare service delivery.

Strategically headquartered in Naples, Florida, HealthLynked operates through three primary divisions: Health Services, Digital Healthcare, and Medical Distribution. Each division supports the company’s mission to revolutionize patient care and health management. Positioned as a potential leader in healthcare AI, HealthLynked is dedicated to shaping the future of the industry over the next 20 years, driving significant advancements in healthcare accessibility and effectiveness through innovation and technology.

Strategic Initiatives and Operational Highlights

The company’s commitment to enhancing global health is evident in its dual goals: transforming healthcare through advanced technology and creating a patient-centric network that accelerates medical discoveries and the development of disease cures.

HealthLynked’s intellectual property portfolio is robust and strategically developed to enhance healthcare delivery and management. In March 2023, HealthLynked was granted a patent for a groundbreaking healthcare-specific wireless access point, known as the “Patient Access Hub.” This technology significantly improves the efficiency of healthcare practices by enabling real-time monitoring of patient flow within facilities. It intelligently determines patients waiting in exam rooms and calculates wait times, alongside other critical practice metrics. This system not only enhances patient experience by reducing unnecessary wait times but also optimizes resource allocation within healthcare settings.

Additionally, in October 2023, HealthLynked filed a patent application for its advanced AI program, ARI (Augmented Real-time Interface). ARI acts as a virtual doctor for patients, capable of performing medical intake, booking appointments, and providing personalized medical recommendations based on a patient’s medical history. By integrating these tasks, ARI streamlines the healthcare process, reducing the administrative burden on healthcare providers and ensuring that patients receive timely and tailored healthcare advice. This AI-driven interface enhances the accessibility and personalization of healthcare, embodying HealthLynked’s commitment to leveraging technology for better health outcomes. The company recently launched HealthLynked 3.2.0, an advanced version of its application, incorporating telemedicine, AI-driven personal healthcare guidance, and remote patient monitoring – setting a new standard in healthcare technology.

Market Position and Future Outlook

According to Facts and Figures Research, a research and consulting firm, the global market for patient-centric healthcare applications is projected to reach $41.6 billion by 2030, growing at a CAGR of 18.77% from 2022. HealthLynked’s offerings align perfectly with this expansive market opportunity, especially with increasing demands for digital health solutions and data management in healthcare.

HealthLynked’s strategic direction, spearheaded by its seasoned management team, is designed to leverage these market dynamics, enhancing patient engagement and healthcare efficiency on a global scale.

Management Team

Michael T. Dent, M.D., Founder, CEO, and Chairman, brings extensive experience from his foundational role at NeoGenomics and leadership in various healthcare and technology sector companies.

David Rosal, CFO, with previous senior roles at Teradata and McDonald’s Corporation, brings a wealth of expertise in financial and business integration strategies essential for growth and operational efficiency.

Chris Hall, CTO, with a strong background in global technology development from his time at Siemens and several patents to his name, is instrumental in driving the innovation and technological advancement at HealthLynked.

Bill Crupi, Operations Manager, has a proven track record in streamlining operations and enhancing productivity across multiple sectors within the healthcare industry. His expertise is crucial in maintaining the operational excellence that HealthLynked is known for.

Michael Paisan, Director of Investor Relations, leverages his extensive experience in finance and communications to enhance HealthLynked’s relationships with investors and stakeholders, ensuring transparent and effective communication of the company’s value and growth strategy.

Gagan Babber, Manager of Software Development, oversees the HealthLynked development teams based in the U.S. and India. With a robust background in engineering and software development, he plays a critical role in guiding the technological direction of HealthLynked’s products. His expertise in developing scalable, innovative software solutions is essential for driving the company’s technical initiatives forward and ensuring that HealthLynked stays at the forefront of digital healthcare technology.

HealthLynked Corp. (OTCQB: HLYK), closed Wednesday's trading session at $0.0257, up 38.5445%, on 1,082,675 volume. The average volume for the last 3 months is 409,240 and the stock's 52-week low/high is $0.0031/$0.0981.

Recent News

• HealthLynked Corp. (OTCQB: HLYK) - IT Professionals Suggest How Healthcare Data Protection Can Be Enhanced
• InvestorNewsBreaks - HealthLynked Corp. Completes $3 Million Cash Consideration from ACO Health Partners Sale
• InvestorNewsBreaks - HealthLynked Corp. Restructures for Growth, Reports Declines in Revenue and Increased Losses in Q3 2024

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

• PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
• PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
• PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
• Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Wednesday's trading session at $0.06028, up 13.9509%, on 28,948 volume. The average volume for the last 3 months is 5,606,080 and the stock's 52-week low/high is $0.03/$1.19.

Recent News

• PaxMedica Inc. (NASDAQ: PXMD) - Autism Prevalence Surges Globally, Raising Concerns Among Healthcare Experts
• New Computational Model Explains Behavioral and Neural Differences in ASD
• Study Finds That Pollution Increases Autism Risk

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $0.116, up 4.5987%, on 41,104,643 volume. The average volume for the last 3 months is 19,633,670 and the stock's 52-week low/high is $0.0955/$3050.00.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Research Shows Brain Tumors Grow by Hijacking Circadian Clocks
• InvestorNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11
• AI Model Promises New Way to Detect Brain Malignancies

Brera Holdings PLC (NASDAQ: BREA)

The QualityStocks Daily Newsletter would like to spotlight Brera Holdings PLC(NASDAQ: BREA).

Brera Holdings PLC (NASDAQ: BREA) is an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach. The company capitalizes on opportunities to earn tournament prizes, secure sponsorships, collect transfer fees, provide professional sports consulting services, and enhance the valuation of its clubs.

Brera Holdings builds on the legacy of Brera FC, an international football club (referred to as soccer in the U.S.), that it acquired in July 2022. Established in 2000 and based in Milan, Italy, Brera FC has distinguished itself by cultivating an alternative football legacy. In October 2024, the Internet Marketing Association awarded Brera FC with the Social Impact Through Soccer accolade at its IMPACT 5050 Conference, recognizing the club’s global perspective and positive contributions to society.

The company’s growth strategy focuses on unlocking value from undervalued sports clubs and talent, driving innovation, and generating socially impactful outcomes. Brera Holdings is actively expanding its Global Sports Group, acquiring professional football and other sports clubs in emerging markets such as Africa, Asia, and Europe.

By targeting top-division teams in less mainstream markets, Brera Holdings aims to strengthen its competitive position in regional tournaments, including those organized by the Union of European Football Associations (UEFA). These acquisitions are expected to enhance sponsorship revenues and create new growth opportunities.

Leveraging its expertise in capital raising and revenue generation, Brera Holdings also anticipates growing demand for its consulting services, providing advisory support to sports clubs, associations, investors, and others. Brera Holdings is headquartered in Dublin, Ireland, with additional offices in Milan, Italy.

Sporting Assets

Brera Holdings continues to grow its global sports portfolio with a series of strategic acquisitions and innovations, including the FENIX Trophy Tournament, a pan-European, non-professional football competition. Launched in September 2021 and organized by Brera FC, the tournament has been recognized by UEFA and described by BBC Sport as “the Champions League for amateurs.” In 2023, Brera FC hosted the tournament’s finals at Milan’s iconic San Siro Stadium.

In March 2023, Brera Holdings expanded into Africa by establishing Brera Tchumene FC in Mozambique. Starting in the country’s Second Division League, the team quickly earned promotion to Moçambola, Mozambique’s First Division League, by November 2023.

In April 2023, Brera Holdings further strengthened its European presence by acquiring a 90% stake in Fudbalski Klub Akademija Pandev, a first-division football team in North Macedonia. This acquisition provides access to two major UEFA competitions, solidifying the company’s position in European football.

Brera Holdings’ reach extends beyond football. In July 2023, it acquired majority ownership of UYBA Volley, an Italian Serie A1 women’s professional volleyball team, demonstrating its commitment to diversifying within top-tier sports.

In September 2023, Brera Holdings entered the Mongolian football market by acquiring Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team. For the 2024 season, the club was rebranded as Brera Ilch FC, further expanding Brera’s global footprint.

In January 2024, Brera Holdings initiated a proactive search for an Italian Serie B football club, aligning with its goal of bringing multi-club ownership opportunities to mass investors through its Nasdaq-listed shares.

In February 2024, the Brera Holdings Advisory Board was established with MLS founder and World Cup director Alan Rothenberg, luxury lifestyle executive Massimo Ferragamo, sports business leaders Paul Tosetti and Marshall Geller, and Italian football icon Giuseppe Rossi.

In June 2024, the North Macedonian women’s football club Tiverija Strumica officially became part of the Brera family with the establishment of a joint-stock company controlled by Brera Holdings called Women’s Football Club Tiverija Brera AD Strumica (“Brera Tiverija”). Brera Tiverija is now a wholly-owned subsidiary of Brera Strumica FC.

In September 2024 Brera announced that it signed an exclusive letter of intent to acquire an Italian Serie B club (the “LOI” and the “Club”). According to a CFA report published in June 2024, this expected strategic transaction, for an estimated purchase price of $21.6 million, would add first-year annual revenue of $10.8 million to Brera, and that revenue would likely increase by 25% each year for the next three years. The company’s capital valuation, projected the report, would also experience significant appreciation during this period.

In October 2024, Brera was recognized with the 2024 Social Impact Through Soccer Award at IMPACT 5050, an annual event honoring leaders and innovators who significantly impact their industries and communities. This is the second time Brera has won the award.

Market Opportunity

A report from IMARC Group, a global management consulting firm, reveals that the international football market generated approximately $3.3 billion in revenue in 2023, with projections to grow to $4.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 3.6%. Key drivers behind this growth include advancements in digitization, increasing sponsorship and partnership deals between brands and clubs, the rising interest in women’s professional soccer leagues, and the expansion of the e-sports and gaming sector.

In particular, Serie B Italian football clubs seem to present exceptionally attractive investment opportunities. As of September 2024, more than half of these clubs had appreciated between 80-100% in total market value, post-purchase.

As the world’s most-watched and most-played sport, soccer drives significant demand for football-related products and services, contributing to market growth. Broadcasting rights, sponsorships, and endorsement deals are also major revenue sources for clubs and organizations, with an expanding global fanbase generating new opportunities for financial growth, according to the report.

Management Team

With extensive experience in leadership and finance, Daniel McClory currently serves as the Executive Chairman and Director of Brera Holdings, PLC. He co-founded and held the position of Chief Executive Officer at Boustead & Company Limited, and previously served as the Managing Director, Head of Equity Capital Markets, and Head of China at Boustead Securities, LLC. Mr. McClory’s governance experience includes being a Board Director for USA Track & Field and a member of the Eastern Michigan University Champions Advisory Board. Mr. McClory’s expertise encompasses founding and financing equity capital markets, as well as navigating merger and acquisition transactions and initial public offerings. He holds a BS and MS from Eastern Michigan University, where he also received an honorary Doctor of Public Service. In addition to his professional qualifications, he is fluent in both English and Italian.

Pierre Galoppi serves as the CEO, Interim CFO, and director of Brera Holdings. With over 30 years of experience in strategic business and financial services, his career spans a variety of industries, including natural resources, aviation, cybersecurity, telecommunications, tourism, and international marketing. He has worked extensively across Latin America, the Caribbean, Canada, Europe, and the United States. Mr. Galoppi holds dual citizenship in Canada and Italy and is fluent in English, Spanish, Portuguese, Italian, and French. He earned a Bachelor of Commerce degree and an MBA from Concordia University in Montreal.

Maria Xing serves as the Head of Investments and Corporate Development. She is an executive who has specialized in MCO football (soccer) group investments for 777 Partners, where she was involved in sourcing, direct negotiations, due diligence, and closing deals, including acquiring a controlling stake in Brazilian Serie A football club, Vasco da Gama, and investing in Australian Premier League (“A-League”) side, Melbourne Victory FC. She also played a role in other professional sports franchise portfolio management, including topflight professional football clubs in Italy, France, Germany, and Belgium. Her background is in private equity, investment banking, and finance, with prior experience at The Raine Group, Credit Suisse, and EY (Ernst & Young), as well as previous sports industry experience at Liverpool Football Club in international business development. Ms. Xing earned an MBA from the Wharton School of the University of Pennsylvania and a B.S. from the New York University, Stern School of Business.

Brera Holdings PLC (NASDAQ: BREA), closed Wednesday's trading session at $0.85727, up 4.0502%, on 867,325 volume. The average volume for the last 3 months is 1,300,800 and the stock's 52-week low/high is $0.4999/$3.00.

Recent News

• Brera Holdings PLC (NASDAQ: BREA) - InvestorNewsBreaks - Brera Holdings PLC (NASDAQ: BREA) Director Goran Pandev Named Sports Director for North Macedonia's National Teams
• Brera Holdings PLC (NASDAQ: BREA) Announces Initial Closing with Execution of Share Purchase Agreement ('SPA') for Three-Step Acquisition of Serie B Team Juve Stabia
• InvestorNewsBreaks - Brera Holdings PLC (NASDAQ: BREA) Takes Initial Step in Acquiring Majority Stake in Serie B Club Juve Stabia

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)

The QualityStocks Daily Newsletter would like to spotlight Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF).

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County.

The company in October 2022 received permit approval from the Bureau of Land Management (BLM) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023.

The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit.

Arizona Metals Corp. is based in Toronto, Canada.

Projects

Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing.

The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices.

Management Team

Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada.

David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School.

Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services.

Arizona Metals Corp. (OTCQX: AZMCF), closed Wednesday's trading session at $1.07, up 0.9433962%, on 233,966 volume. The average volume for the last 3 months is 171,580 and the stock's 52-week low/high is $1.01/$2.00.

Recent News

• Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) - Feds Move Closer to Authorizing Zinc Mine Expansion in Alaska
• Beijing Moves to Leverage Afghanistan's Mineral Resources
• IXM Reveals EV Demand for Copper Still Intact Despite Sales Slump

Bebuzee Inc. (OTC: BBUZ)

The QualityStocks Daily Newsletter would like to spotlightFathom Bebuzee Inc. (OTC: BBUZ) .

Bebuzee Inc. (OTC: BBUZ), formerly Engage Mobility Inc., is a social platform and streaming service focused on development and deployment of America’s first superapp. The superapp will allow members to watch a wide variety of content, such as movies, series, documentaries and talk shows, on any internet-connected device.

Bebuzee’s technology scans the world’s news, features and information-flow to give its dedicated readers the best of the internet in one place – a one-stop platform for breaking news, interesting and important blogs, videos and photos.

The core features of the superapp include video streaming; photo sharing; Bebuzee Messaging service, which allows users to send text and voice messages and make voice and video calls; Shortbuz, used to make a variety of short-form entertaining videos; Blogbuz, a resource for people without time to scavenge the internet and other sources for news and information; Properbuz global real estate search; global tradesmen search; location reviews of neighborhoods, cities and even regions to help others find their ideal rental or real estate purchase; ShoppingBuz, a unique technology-driven e-commerce platform which gives merchants incredible tools to sell their products; Bebuzee Pay, a mobile payment and digital wallet service that allows users to make mobile payments and online transactions; TravelBuz, an online travel booking service; EventBuz, a ticket exchange and resale platform; and FlightBuz, a flight search engine.

The company is headquartered in Miami.

Introducing the Superapp to Western Markets

A superapp is a mobile phone app that offers a wide range of services within a single platform. This technology allows users to access various services without downloading and switching between multiple apps.

While superapps are popular in many parts of the world, including Latin America, Africa, the Middle East, Asia and Russia, they have achieved little adoption in Western markets. Perhaps the most widely known superapp is WeChat, which is estimated to have as many as 1.24 billion users, mostly in China.

Bebuzee aims to be the first developer to introduce and grow to widespread popularity a superapp in the U.S. and Europe. It took a strong step toward achieving this goal during the COVID-19 pandemic, when Bebuzee’s user base surged by 78% with over 42 million new users.

Whereas most social platforms are generic and only local postings make them somewhat relevant to local communities, Bebuzee has localized its platform for most countries by providing local content, entertainment and information that is frequently updated and refreshed.

The company says the average age of its superapp users is 39, with female users making up 62.8% of its user base. Its monetization strategy includes sales of video advertising, sponsored posts, banner ads and premium listings, as well as promotion of featured brands and property listings.

Market Opportunity

A report from Allied Market Research, a global market research, consulting and advisory firm, estimated that the worldwide superapps market was valued at $58.6 billion in 2022. The report projects the market to expand to $722.4 billion by 2032, growing at a CAGR of 28.9% for the forecast period.

The report identifies a few of the most popular superapps as Rappi in Latin America, Snapp in Iran, Line in Japan and Yandex Go in Russia and Kazakhstan.

Increasing adoption of mobile services and growing advancements in digital technologies are driving the growth of this market. In addition, a rise in government support for promoting the use of superapps is lending to expansion, according to the report.

Integration of blockchain technology in superapps is likewise anticipated to provide numerous opportunities for the expansion of the market during the forecast period, the report states.

Management Team

Joseph Onyero is Founder and CEO of Bebuzee. He has a background of managing multiple products from ideation to market launch and profitable monetization and has been building commercial web presences since 2005. He has worked as a Chief Marketing Officer and in business development. He previously owned and operated a travel and tourism company. He began in 2005 working on the concept and features that have evolved into the Bebuzee suite. He has grown Bebuzee from a living room start-up into a U.S. publicly traded company.

Claudia S. Spagnuolo is Chief Operating Officer at Bebuzee. She began with the company in 2014 as a user experience manager before being promoted to CMO in 2017. She previously worked as an assistant marketing director at the National Secretariat of the union CISL in Italy. Prior to that, she also worked as a researcher at the Complutense University of Madrid on issues of corporate management. She speaks three languages and holds a bachelor’s in political science and a master’s in administration from the University of Perugia in Italy.

Bebuzee Inc. (OTC: BBUZ), closed Wednesday's trading session at $0.043, up 34.375%, on 130,000 volume. The average volume for the last 3 months is 21,670 and the stock's 52-week low/high is $0.0162/$0.1925.

Recent News

• Bebuzee Inc. (OTC: BBUZ) - InvestorNewsBreaks - Bebuzee Inc. (BBUZ) Revolutionizes Content Monetization with Creator-First Super App
• InvestorNewsBreaks - Bebuzee Inc. (BBUZ) Expands Super App with Launch of Bebuzee TV's Six Curated Channels
• TechMediaBreaks - Bebuzee Inc. (BBUZ) Looking to 'Change the Game' via Comprehensive Digital Ecosystem